Article Details

Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 ...

Retrieved on: 2022-01-20 17:46:08

Tags for this article:

Click the tags to see associated articles and topics

Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 .... View article details on hiswai:

Excerpt

Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up